Welcome to our dedicated page for Adagio Medical news (Ticker: ADGM), a resource for investors and traders seeking the latest updates and insights on Adagio Medical stock.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is a medical device company focused on catheter ablation technologies for cardiac arrhythmias, and its news flow centers on the development, clinical evaluation, and commercialization of its Ultra-Low Temperature Cryoablation (ULTC) platform. Company press releases highlight progress with the vCLAS Cryoablation System for ventricular tachycardia, key clinical milestones, financing events, and leadership updates.
Investors and clinicians following ADGM news will see regular updates on the FULCRUM-VT U.S. pivotal IDE study, which Adagio describes as a prospective, multi-center, open-label, single-arm trial designed to evaluate the safety and effectiveness of ULTC for recurring monomorphic ventricular tachycardia. News items include completion of enrollment, preliminary acute safety and effectiveness results presented at a major ventricular arrhythmia symposium, and plans to use study outcomes to support a future PMA application for vCLAS.
Adagio’s news releases also cover capital markets activity, such as the announcement and closing of a private placement intended to fund FDA submission activities, next-generation ULTC catheter development, and expansion of manufacturing and commercial readiness. Additional coverage includes governance and leadership changes, including the appointment of a Chief Business Officer who also serves as Chief Financial Officer, the addition of an industry veteran to the Board of Directors, and the hiring of senior executives in global sales and manufacturing and operations.
For those tracking ADGM, the news stream provides insight into clinical data disclosures, regulatory strategy, financing transactions, conference presentations, and board and management developments that the company identifies as important to its ULTC-based ventricular tachycardia program.
Adagio Medical Holdings (Nasdaq: ADGM) has announced its participation in the Stifel 2024 Healthcare Conference. CEO & President Olav Bergheim will deliver a presentation on Monday, November 18, at 9:45 a.m. Eastern Time at the Lotte New York Palace Hotel in New York. The company, which specializes in catheter ablation technologies for cardiac arrhythmia treatment, will provide a live audio webcast of the presentation, accessible through the 'Investors' section of their website. A replay will also be available for those unable to attend the live session.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, scheduled for October 11-12, 2024, in New York. The company's Ultra-Low Temperature Cryoablation (ULTC) technology will be featured in the symposium's scientific program.
Two presentations are highlighted:
- Dr. Atul Verma will present Cryocure-VT: One-year Results and Next Steps (FULCRUM-VT) on October 11 at 4:40 p.m. ET
- Professor Dr. Roland Tilz will present a recorded case on PVC Ablation using Ultra-low Cryoablation on October 12 at 12:35 p.m. ET
Olav Bergheim, President and CEO of Adagio, expressed pride in supporting the event and anticipation for discussing their technology and clinical program with experts in the field.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for cardiac arrhythmias, has provided a business update highlighting significant milestones. The company has obtained CE Mark approval and initiated the commercial launch of its vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for ventricular tachycardia (VT) treatment in Europe. Additionally, Adagio has received FDA approval for the FULCRUM-VT Pivotal IDE study in the US, with patient enrollment expected to begin in September.
The company recently closed a business combination with ARYA Sciences Acquisition Corp IV, resulting in its listing on the Nasdaq Capital Market under the ticker symbol 'ADGM'. This transaction, along with concurrent financings, raised approximately $84.2 million, leaving the company with a proforma cash-on-hand of about $35 million after closing.